Literature DB >> 8673859

Recommendations for the registration of new chemical entities used in the prevention and treatment of osteoporosis.

J Y Reginster, J E Compston, E A Jones, J M Kaufman, M Audran, G Bouvenot, L Frati, G Mazzuoli, C Gennari, E M Lemmel.   

Abstract

Entities:  

Mesh：

Year:  1995        PMID： 8673859     DOI： 10.1007/bf00298877

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN： 0171-967X            Impact factor:   4.333


× No keyword cloud information.
  9 in total

Review 1.  Connectivity of cancellous bone: assessment and mechanical implications.

Authors:  J E Compston
Journal:  Bone       Date:  1994 Sep-Oct       Impact factor: 4.398

Review 2.  Basic biomechanical measurements of bone: a tutorial.

Authors:  C H Turner; D B Burr
Journal:  Bone       Date:  1993 Jul-Aug       Impact factor: 4.398

Review 3.  Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  1994

4.  Changing incidence and residual lifetime risk of common osteoporosis-related fractures.

Authors:  J B Lauritzen; P Schwarz; B Lund; P McNair; I Transbøl
Journal:  Osteoporos Int       Date:  1993-05       Impact factor: 4.507

5.  Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group.

Authors:  S R Cummings; D M Black; M C Nevitt; W Browner; J Cauley; K Ensrud; H K Genant; L Palermo; J Scott; T M Vogt
Journal:  Lancet       Date:  1993-01-09       Impact factor: 79.321

6.  [Postmenopausal osteoporosis: clinical characteristics in patients first vertebral crush fracture. Results of the GRIO National Multicenter Survey. Groupe de Recherche et d'Information sur les Osteoporoses].

Authors:  C Ribot; J M Pouillès
Journal:  Rev Rhum Ed Fr       Date:  1993-06

7.  The predictive value of bone loss for fragility fractures in women: a longitudinal study over 15 years.

Authors:  P Gärdsell; O Johnell; B E Nilsson
Journal:  Calcif Tissue Int       Date:  1991-08       Impact factor: 4.333

Review 8.  Perspective. How many women have osteoporosis?

Authors:  L J Melton; E A Chrischilles; C Cooper; A W Lane; B L Riggs
Journal:  J Bone Miner Res       Date:  1992-09       Impact factor: 6.741

9.  Age and bone mass as predictors of fracture in a prospective study.

Authors:  S L Hui; C W Slemenda; C C Johnston
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808
  9 in total
  16 in total

1.  New drugs for osteoporosis. Comparison of the costs and required returns with those of other drugs intended for long-term use.

Authors:  M Edwards
Journal:  Pharmacoeconomics       Date:  1999-03       Impact factor: 4.981

Review 2.  Alendronate: an update of its use in osteoporosis.

Authors:  M Sharpe; S Noble; C M Spencer
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Recommendations for the registration of agents used in the prevention and treatment of glucocorticoid-induced osteoporosis.

Authors:  J E Compston; M Audran; B Avouac; G Bouvenot; J Devogelaer; R Eastell; F Fabris; C Gennari; E A Jones; J M Kaufman; E Lemmel; G Mazzuoli; D M Reid; J D Ringe; L Vanhaelst; R Ziegler; J Y Reginster
Journal:  Calcif Tissue Int       Date:  1996-11       Impact factor: 4.333

4.  The GREES recommendations for the registration of new drugs in the prevention and treatment of osteoporosis.

Authors:  J A Kanis; P Delmas; P Meunier; C Johnston; J Bonjour; C Christiansen; R Lindsay; H Bone
Journal:  Calcif Tissue Int       Date:  1996-11       Impact factor: 4.333

Review 5.  Parathyroid hormone in the treatment of involutional osteoporosis: back to the future.

Authors:  J Y Reginster; A N Taquet; G Fraikin; C Gosset; B Zegels
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

6.  Quality of life as outcome in the treatment of osteoporosis: the development of a questionnaire for quality of life by the European Foundation for Osteoporosis.

Authors:  P Lips; C Cooper; D Agnusdei; F Caulin; P Egger; O Johnell; J A Kanis; U Liberman; H Minne; J Reeve; J Y Reginster; M C de Vernejoul; I Wiklund
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

7.  Validation of the Quality-of-Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO-26) in Korean population.

Authors:  Jung Sub Lee; Jong Ki Shin; Seung Min Son; Sung Jin An; Sung Shik Kang
Journal:  Rheumatol Int       Date:  2014-01-11       Impact factor: 2.631

Review 8.  Identification of vertebral fractures: an update.

Authors:  L Ferrar; G Jiang; J Adams; R Eastell
Journal:  Osteoporos Int       Date:  2005-05-03       Impact factor: 4.507

9.  Design and methodology of the phase 3 trials for the clinical development of strontium ranelate in the treatment of women with postmenopausal osteoporosis.

Authors:  P J Meunier; J Y Reginster
Journal:  Osteoporos Int       Date:  2003-03-12       Impact factor: 4.507

Review 10.  The impact of fragility fracture on health-related quality of life : the importance of antifracture therapy.

Authors:  Ted Xenodemetropoulos; Shawn Davison; George Ioannidis; Jonathan D Adachi
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.